Results 11 - 20 of 20 : Previous 1 2
Is Amgen's Nplate a Blockbuster?
Amgen gets a positive recommendation from European officials.
Ligand and Glaxo Like the FDA's Answer
Good news arrives for blood-clot buster Promacta.
See what the best CAPS players recommend now.
Will These Delayed Drugs Make It to Market?
The FDA is taking its own sweet time.
Growth from the big biotech returns.
A Pfizer Drug With a Cloudy Future
The company offers another drug with mixed odds to the FDA.
And it's a good one for a change.
The Food and Drug Administration's impending ruling will determine the drugmaker's near-term fate.
The FDA delays its review of blood-disorder drug Promacta.
Companies That Pay Out ... and Drop
An explanation of why a stock price falls after a large one-time dividend payout.